Real-world outcomes of myeloma treatment in the UK
Part of Cancer clinical trials.
This study looks at how newly diagnosed myeloma patients in the UK respond to a specific drug combination (daratumumab, lenalidomide, and dexamethasone) when used as first-line treatment. Researchers want to understand how well this treatment works in everyday practice, outside of controlled clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with newly diagnosed multiple myeloma (NDMM)
- You were not eligible for an autologous stem cell transplant (a bone marrow/stem cell transplant using your own cells) at the time of your diagnosis
- You started treatment with daratumumab, lenalidomide, and dexamethasone (DRd) as your first-line therapy after September 2023
- You have at least 3 months of treatment and follow-up medical records available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tailoring myeloma treatment based on how well you respond to initial therapy and your overall health status can improve outcomes. You'll receive standard first-line treatment (three drugs: daratumumab, lenalidomide, and dexamethasone) and then be assigned to a personalized pathway based on your response and fitness level.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This trial tests a combination of two drugs, daratumumab and lenalidomide, for patients with multiple myeloma that has not responded to previous treatments. It aims to see if this regimen can help when other therapies have stopped working.
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.